Supplementary data for 'Modeling acquired resistance to the second-generation androgen receptor antagonist enzalutamide in the TRAMP model of prostate cancer'.

This copy of the Supplementary Material is subject to the same embargo as the post-print and will be available here from 06/02/21.

Content:
Model parameterization
Vehicle and enzalutamide:
-In vitro experiments
Figures SMM1 & SMM2
-In vivo experiments (under skin)
Figures SMM3 & SMM4

Mathematical model for combo therapies: enzalutamide-everolimus or
enzalutamide-cabazitaxel
Everolimus:
-From in vitro experiments
Figures SMM5 & SMM6
-In vivo experiments (under skin)
Figure SMM7

Cabazitaxel:
-In vitro experiments
Figures SMM8 & SMM9
-In vivo experiments (under skin)
Figure SMM10

Sensitivity Analysis